Chemomab Therapeutics Ltd. announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market notifying the company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq’s minimum $1.00 bid price per share requirement. If at any time until November 4, 2024, the closing bid price of Chemomab’s American Depositary Shares is at least $1.00 per ADS for a minimum of 10 consecutive trading days, Nasdaq will provide written confirmation of compliance to the company and the matter will be closed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics upgraded to Outperform from Perform at Oppenheimer
- Chemomab Annual Meeting and Key Proposals
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
- Chemomab Therapeutics reports publication on its CCL24 target, SSc
Questions or Comments about the article? Write to editor@tipranks.com